Daniel S.W. Tan
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer(2014)1,469 cited
- → Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates(2018)1,349 cited
- → First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study(2017)1,138 cited
- → Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer(2020)977 cited
- → Efficacy of Selpercatinib in RET -Altered Thyroid Cancers(2020)741 cited
- → Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations(2022)728 cited
- → Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer(2021)607 cited
- → A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer(2012)552 cited
- → Genomic landscape of lung adenocarcinoma in East Asians(2020)530 cited
- → Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial(2016)467 cited